Company intelligence / Profile preview

Cognito Therapeutics

Cambridge, Massachusetts, United Statescognitotx.com ↗

Ownership: Private
Employees: ~75
Development stage: Phase 2

Overview

Cognito's Phase 2 OVERTURE trial in Alzheimer’s patients showed significant slowing of cognitive decline and brain atrophy—69% reduction in brain volume loss and 77% slowing of functional decline compared to control. No serious treatment-limiting adverse events were reported. The pivotal HOPE Phase 3 trial (~670 participants) is currently enrolling to further validate safety/efficacy before regulatory submission. The device received FDA Breakthrough Device Designation. While the therapy did not reduce amyloid burden in the brain per imaging data from OVERTURE, it did significantly slow whole-brain atrophy.

Therapeutic areas: CardiovascularNeurology
Modalities: DeviceNon-pharmacological therapy
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

Spectris

Phase 2

Indications: Alzheimer's disease

Partnerships

Not specifically disclosed; no major pharma partnerships publicly announced as of June 2025.

Beyond the preview

Go deeper on Cognito Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cognito Therapeutics.

Explore the full profile